28
Participants
Start Date
September 1, 2024
Primary Completion Date
July 1, 2027
Study Completion Date
July 1, 2027
Selinexor, anti-PD-1 antibody and P-GemOx
Selinexor, 40mg, qw, po; Pegaspargase, 2500U/m2, IM, d1; Gemcitabine, 1000mg/m2, i.v., d1, d8; Oxaliplatin, 130mg/m2, i.v., d1; anti-PD1 antibody, 200mg, d2, i.v. (21d cycle);
Ruijin Hospital
OTHER